Articles

Analysts demand news on next Lilly blockbuster

Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.

Read More

Charges drive down first-quarter profit at Lilly

First-quarter profit fell at Eli Lilly and Co. as the company recorded restructuring charges due to its downsizing and higher research costs as it tries to develop new drugs to help it shrug off its looming patent expirations.

Read More

Zimmer goes on offensive against lawyers

The Warsaw-based maker of orthopedic implants has filed suit to stop a Detroit-area law firm from making allegedly false claims and using its trademarks on websites designed to attract plaintiffs to sue Zimmer over one of its knee-replacement implants called NexGen.

Read More

Another suit filed in Emmis, financier dispute

Emmis Communications Corp. is accusing Alden Global Capital, which once backed Emmis CEO Jeff Smulyan’s attempt to take the company private, of violating the “short-swing rule.” This is the third suit involving the parties since Smulyan called off the move last year.

Read More

Drugmakers call off animal-health deal, possible asset sale

Drugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies considered selling.

Read More

Allison Transmission files for $750M IPO

Allison Transmission Inc. is counting on upgrades to truck and bus fleets in countries like China and India for its future growth, the company revealed in a filing it made Friday to raise up to $750 million through an initial public offering.

Read More

PROXY CORNER: Eli Lilly and Co.

Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.

Read More

Lechleiter: After the deluge, we’ll be fine

Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.

Read More

Lilly agrees to buy European animal health company

Elanco, the animal health division of Eli Lilly and Co., has agreed to acquire Jannsen Animal Health, a subsidiary of New Jersey-based Johnson & Johnson, pending regulatory approval. Financial terms of the deal were not disclosed.

Read More